Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
AssigneesUniversity of Massachusetts, Massachusetts Eye and Ear Infirmary
InventorsAnn Marshak-Rothstein, Meredith Gregory-Ksander, Bruce Ksander
Life of this patent
Estimating the term…
Abstract
Methods for treating glaucoma and/or Fas ligand-dependent inflammatory conditions in a subject using soluble Fas ligand (sFasL) or a fragment thereof, which may be rAAV-mediated delivery of sFasL or a fragment thereof to a subject.
Claims29
A method of treating glaucoma in a subject, the method comprising:
- administering to a subject in need thereof an effective amount of recombinant adeno-associated virus (rAAV), wherein the rAAV comprises (i) capsid protein and (ii) a nucleic acid engineered to express soluble Fas ligand or a fragment thereof.
A method of treating a Fas ligand-dependent inflammatory condition, comprising:
- administering to a subject in need thereof an effective amount of recombinant adeno-associated virus (rAAV), wherein the rAAV comprises (i) a capsid protein, and (ii) a nucleic acid engineered to express soluble Fas ligand or a fragment thereof.
A method of treating a Fas ligand-dependent inflammatory condition, comprising:
- (a) detecting presence or absence of membrane-bound Fas ligand (mFasL) and/or soluble Fas ligand (sFasL) in a tissue of a subject,
- (b) treating the subject based on presence or absence of mFasL and/or sFasL, wherein treating the subject comprises administering to the subject an effective amount of recombinant adeno-associated virus (rAAV), wherein the rAAV comprises (i) a capsid protein, and (ii) a nucleic acid engineered to express sFasL or a fragment thereof.
A method of administering soluble FasL (sFasL) or a fragment thereof to a subject, wherein the subject has age-related elevated intraocular pressure, the method comprising:
- intraocularly administering a recombinant adeno-associated virus (rAAV) that comprises a nucleic acid engineered to express sFasL or a fragment thereof.
A recombinant adeno-associated virus (rAAV) comprising:
- an AAV capsid protein having a sequence as set forth in SEQ ID NO:
- 1, and
- a nucleic acid engineered to express soluble Fas ligand (sFasL) or a fragment thereof.
An isolated nucleic acid having the sequence as set forth in SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.